Autolus Therapeutics (AUTL) – Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Autolus Therapeutics (NASDAQ: AUTL) in the last few weeks:

• 3/31/2026 – Autolus Therapeutics had its price target lowered by Mizuho from $12.00 to $10.00. They now have an “outperform” rating on the stock.
• 3/27/2026 – Autolus Therapeutics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $10.00 price target on the stock.
• 3/25/2026 – Autolus Therapeutics was upgraded by Truist Financial Corporation to “strong-buy”.
• 3/13/2026 – Autolus Therapeutics was upgraded by Zacks Research from “strong sell” to “hold”.
• 2/17/2026 – Autolus Therapeutics is now covered by HC Wainwright. They set a “buy” rating and a $9.00 price target on the stock.
• 2/17/2026 – Autolus Therapeutics is now covered by HC Wainwright. They set a “buy” rating and a $9.00 price target on the stock.

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.